Personalis’ CEO, John West, first became involved in DNA sequencing and DNA sequence interpretation in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at MRC Cambridge, UK for sequence assembly and analysis. In the 1990’s Mr. West was General Manager and subsequently President of Princeton Instruments, a company focused on low light scientific imaging. This technology was used in a number of fluorescent automated DNA sequencing developments. In 2001 Mr. West joined then market leader Applied Biosystems as Vice President of Genetic Analysis. He was subsequently promoted to VP, DNA Platforms. While at Applied Biosystems Mr. West’s group introduced the model 3730xl Genetic Analyzer. This product became the mainstay of almost every major genome center in the world.
In 2004, Mr. West moved to be CEO of Solexa Ltd, a venture capital backed UK company focused primarily on single-molecule DNA sequencing. Mr. West realized that the company’s recent acquisition of DNA cluster technology could be transformative. In 2005 he led Solexa’s reverse merger into US-based and Nasdaq-listed Lynx Therapeutics, and led two PIPE financings totaling almost $100M. The company introduced its first system in mid-2006. Mr. West negotiated the January 2007 acquisition of Solexa by Illumina, Inc for approximately $600M, and stayed as VP of the DNA sequencing business there into 2008. During this time, Illumina became the world leader in next generation DNA sequencing.
From 2009 through mid-2011 Mr. West served as CEO of ViaCyte, Inc, a company leveraging stem cell technology to develop a diabetes cell therapy.
In late 2009 Mr. West’s family became the first healthy family of four to be sequenced. Their experience working with the Stanford team on genome interpretation led to the foundation of Personalis.
Mr. West received a BS and MS engineering degrees from MIT, and earned an MBA from the University of Pennsylvania’s Wharton School of Business.
Richard Chen, MD, MS
Christian Haudenschild, PhD
Adam Lowe joined Personalis in June 2013 as Vice President of Marketing. Prior to joining Personalis, Adam served as Vice President of Commercial Operations at Oxford Nanopore Technologies. Prior to Oxford, he spent 5 years at Illumina where he built and led Illumina’s product marketing/management team for next-generation sequencing. Mr. Lowe also served as Director of Scientific Operations at Applied Biosystems (now Life Technologies), worked in business development at Agilent Technologies, co-founded a small biotechnology consulting firm, and was the first employee of Genetic Health, a healthcare startup focused on building on-line tools for risk assessment, management and research on the genetic basis of common disease.
Prior to joining the commercial world, Mr. Lowe co-founded and was the Director of HIV Services, the primary care HIV medicine program at Chase Brexton Health Services, now the largest provider of HIV-related healthcare in the state of Maryland. Mr. Lowe received a B.A. degree in Social and Behavioral Science from Johns Hopkins University.